EGFR、ALK双突变非小细胞肺癌1例

doi:10.3760/cma.j.issn.1007-1245.2022.18.026

国际医药卫生导报 ›› 2022, Vol. 28 ›› Issue (18): 2627-2630.DOI: 10.3760/cma.j.issn.1007-1245.2022.18.026

EGFR、ALK双突变非小细胞肺癌1例

宋鹏程¹ 祝晓娜² 高祥敬¹ 鞠莎¹ 李飞¹

¹青岛大学附属威海市中心医院呼吸与危重症医学科，威海　264400； ²青岛大学附属威海市中心医院健康管理中心，威海　264400

收稿日期:2022-05-19 出版日期:2022-09-15 发布日期:2022-10-12
通讯作者: 宋鹏程，Email：272469188@qq.com

A case of EGFR and ALK double mutations in non-small cell lung cancer

Song Pengcheng¹, Zhu Xiaona², Gao Xiangjing¹, Ju Sha¹, Li Fei¹

¹Department of Respiratory and Critical Care Medicine, Weihai Central Hospital Affiliated to Qingdao University, Weihai 264400, China; ²Health Management Center, Weihai Central Hospital Affiliated to Qingdao University, Weihai 264400, China

Received:2022-05-19 Online:2022-09-15 Published:2022-10-12
Contact: Song Pengcheng, Email: 272469188@qq.com

摘要/Abstract

摘要： 表皮生长因子受体（epithelial growth factor receptor，EGFR）和间变性淋巴瘤激酶（anaplastic lymphoma kinase，ALK）双突变作为罕见分子事件，发生率为1.3%～1.6%，其临床病理特点还不是很清楚，治疗策略尚无定论，尤其是靶向药物的选择。本文报道威海市中心医院2021年11月收治的1例EGFR和ALK基因双突变共存女性肺腺癌患者临床资料，并复习相关文献，以期为该类患者的治疗提供临床借鉴，对于其治疗经过及治疗过程中出现的不良反应进行了随访观察，现报道如下。

关键词: 肺恶性肿瘤, 基因突变, 靶向药物

Abstract: The double mutation of epithelial growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) is a rare molecular event, with an incidence of 1.3%-1.6%. Its clinicopathological features are still unclear, and no final conclusion has yet been reached on its therapeutic strategies, especially on the selection of its targeted drugs. This paper reports the clinical data of one female lung adenocarcinoma patient with the coexistence of double mutations of EGFR and ALK admitted to Weihai Central Hospital in November 2021, and reviews the pertinent literatures, hoping to provide clinical references for the treatment of this kind of disease. Moreover, follow-up observation is performed for her treatment processes and adverse reactions during the treatment, and now it is reported as follows.

Key words: Lung malignant tumors, Gene mutation, Targeted drugs

宋鹏程祝晓娜高祥敬鞠莎李飞. EGFR、ALK双突变非小细胞肺癌1例[J]. 国际医药卫生导报, 2022, 28(18): 2627-2630.

Song Pengcheng, Zhu Xiaona, Gao Xiangjing, Ju Sha, Li Fei. A case of EGFR and ALK double mutations in non-small cell lung cancer[J]. International Medicine and Health Guidance News, 2022, 28(18): 2627-2630.

参考文献

[1] 郑雪婷,柳德灵,宋颖芳,等. 左肺腺癌伴EGFR基因及EML4-ALK融合基因双突变一例[C]. 2016:1-1.
[2] Thumallapally N, Yu H, Farhan M, et al. Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature[J].J Pharm Pract,2018,31(2):244-248.DOI:10.1177/0897190017704751.
[3] 冯征,文苗苗,王雪娇,等. 中国西北地区非小细胞肺癌EGFR、ALK、ROS1基因突变和临床病理特征分析[J]. 临床肿瘤学杂志,2021,26(1):29-33.DOI:10.3969/j.issn.1009-0460.2021.01.005.
[4] 王鑫,钟殿胜. 非小细胞肺癌EGFR和ALK基因双突变研究进展[J]. 中国肺癌杂志,2018,21(9):686-691. DOI:10.3779/j.issn.1009-3419.2018.09.07.
[5] 黄娟. 肺腺癌EGFR及ALK突变状态与患者一般资料、胸部CT影像特征的相关性分析[D]. 南昌:南昌大学,2018.
[6] 中国抗癌协会肺癌专业委员会. EGFR-TKI不良反应管理专家共识[J]. 中国肺癌杂志,2019,22(2):57-81. DOI:10.3779/j.issn.1009-3419.2019.02.01.
[7] 王可,李娟,孙建国,等. 间变性淋巴瘤激酶抑制剂不良反应管理西南专家建议(2021年版)[J]. 中国肺癌杂志,2021,24(12):815-828.DOI:10.3779/j.issn.1009-3419.2021. 102.32.
[8] 赵文文,赵文飞,冯青青,等. EGFR和ALK基因双突变非小细胞肺癌1例报告并文献复习[J]. 青岛大学学报(医学版),2021,57(1):146-148.DOI:10.11712/jms.2096-5532. 2021.57.059.
[9] 王梦瑶,任敦强,郭彩宏,等. EGFR双突变非小细胞肺癌患者临床特征分析[J]. 中国肺癌杂志,2018,21(8):594-599. DOI:10.3779/j.issn.1009-3419.2018.08.05.
[10] 姚梅宏,郑宇辉,杨映红,等. 伴有EGFR突变与ALK融合共存的肺腺癌六例临床病理学特征[J]. 中华病理学杂志,2021,50(12):1369-1371.DOI:10.3760/cma.j.cn112151- 20210501-00338.
[11] Zhao N, Zheng SY, Yang JJ, et al. Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review[J].Clin Lung Cancer,2015,16(2):e5-e9. DOI:10.1016/j.cllc.2014. 11.001.

EGFR、ALK双突变非小细胞肺癌1例

A case of EGFR and ALK double mutations in non-small cell lung cancer

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

[1]	蓝惠华潘燕如张梦情黄榕张玲. 闽南地区21例罕见地中海贫血基因突变分析[J]. 国际医药卫生导报, 2022, 28(19): 2758-2762.
[2]	赵柳燕宋守君薛海波. 分子靶向药物治疗难治性甲状腺癌的疗效及安全性的meta分析[J]. 国际医药卫生导报, 2022, 28(17): 2369-2376.